Veracyte, Inc. (VCYT) EPS Estimated At $-0.24

October 13, 2018 - By Adrian Mccoy

Veracyte, Inc. (NASDAQ:VCYT) LogoInvestors sentiment increased to 1.54 in 2018 Q2. Its up 0.50, from 1.04 in 2018Q1. It improved, as 13 investors sold Veracyte, Inc. shares while 15 reduced holdings. 15 funds opened positions while 28 raised stakes. 20.90 million shares or 0.05% less from 20.91 million shares in 2018Q1 were reported.
Goldman Sachs Gru has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). 3.55 million were accumulated by Tpg Grp Inc (Sbs) Advisors Inc. Meeder Asset Mgmt Incorporated holds 0% or 8,996 shares. 17,000 are owned by State Of Wisconsin Invest Board. Ameritas Investment Prns holds 1,394 shares or 0% of its portfolio. Moreover, Board Of Trustees Of The Leland Stanford Junior University has 0.01% invested in Veracyte, Inc. (NASDAQ:VCYT). Northern Trust Corporation reported 271,588 shares. Bnp Paribas Arbitrage reported 701 shares. California Employees Retirement holds 0% or 148,600 shares. First Light Asset Mngmt Limited Liability Company owns 881,983 shares for 1.28% of their portfolio. Blair William And Il, Illinois-based fund reported 15,250 shares. Financial Bank Of America Corp De reported 81,566 shares stake. Prelude Capital Mngmt Lc invested in 180,790 shares. Legal General Group Public Limited Com owns 4,106 shares for 0% of their portfolio. Morgan Stanley holds 0% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT) for 178,031 shares.

Since June 12, 2018, it had 0 insider buys, and 10 selling transactions for $6.73 million activity. Anderson Bonnie H also sold $575 worth of Veracyte, Inc. (NASDAQ:VCYT) on Tuesday, July 24. TREU JESSE I had sold 500,000 shares worth $5.41M on Tuesday, July 31.

Analysts expect Veracyte, Inc. (NASDAQ:VCYT) to report $-0.24 EPS on November, 5.They anticipate $0.03 EPS change or 14.29 % from last quarter’s $-0.21 EPS. After having $-0.18 EPS previously, Veracyte, Inc.’s analysts see 33.33 % EPS growth. The stock decreased 0.20% or $0.02 during the last trading session, reaching $10.18. About 412,093 shares traded or 4.52% up from the average. Veracyte, Inc. (NASDAQ:VCYT) has risen 35.12% since October 13, 2017 and is uptrending. It has outperformed by 19.50% the S&P500.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $401.52 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

More important recent Veracyte, Inc. (NASDAQ:VCYT) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Affimed’s Cancer Drug Placed On Clinical Hold, Celgene’s Positive Scalp Psoriasis Trial” on October 09, 2018, also Streetinsider.com published article titled: “Veracyte (VCYT) Reports New Data from Six Studies Highlighting ‘Real World’ Performance of Afirma GSC and …”, Seekingalpha.com published: “Veracyte’s Envisa test shows value as aid in detecting lung disease” on October 08, 2018. More interesting news about Veracyte, Inc. (NASDAQ:VCYT) was released by: Seekingalpha.com and their article: “Key events next week – healthcare” with publication date: September 28, 2018.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>